BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 8361764)

  • 1. Novel DNA binding of p53 mutants and their role in transcriptional activation.
    Zhang W; Funk WD; Wright WE; Shay JW; Deisseroth AB
    Oncogene; 1993 Sep; 8(9):2555-9. PubMed ID: 8361764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The requirement of the carboxyl terminus of p53 for DNA binding and transcriptional activation depends on the specific p53 binding DNA element.
    Zhang W; Guo XY; Deisseroth AB
    Oncogene; 1994 Sep; 9(9):2513-21. PubMed ID: 8058314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inactive p53 mutants may enhance the transcriptional activity of wild-type p53.
    Zhang W; Shay JW; Deisseroth A
    Cancer Res; 1993 Oct; 53(20):4772-5. PubMed ID: 8402659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heterogeneity of transcriptional activity of mutant p53 proteins and p53 DNA target sequences.
    Chen JY; Funk WD; Wright WE; Shay JW; Minna JD
    Oncogene; 1993 Aug; 8(8):2159-66. PubMed ID: 8336941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microinjection of monoclonal antibody PAb421 into human SW480 colorectal carcinoma cells restores the transcription activation function to mutant p53.
    Abarzúa P; LoSardo JE; Gubler ML; Neri A
    Cancer Res; 1995 Aug; 55(16):3490-4. PubMed ID: 7627952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The DNA-binding and transcription-activation abilities of p53 are necessary but not sufficient for its antiproliferation function.
    Zhang W; Randhawa GS; Guo XY; Deisseroth AB
    Cell Growth Differ; 1994 Jul; 5(7):705-10. PubMed ID: 7947385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct regions of p53 have a differential role in transcriptional activation and repression functions.
    Sang BC; Chen JY; Minna J; Barbosa MS
    Oncogene; 1994 Mar; 9(3):853-9. PubMed ID: 8108128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Positive and negative regulation of deltaN-p63 promoter activity by p53 and deltaN-p63-alpha contributes to differential regulation of p53 target genes.
    Harmes DC; Bresnick E; Lubin EA; Watson JK; Heim KE; Curtin JC; Suskind AM; Lamb J; DiRenzo J
    Oncogene; 2003 Oct; 22(48):7607-16. PubMed ID: 14576823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Specific DNA binding by different classes of human p53 mutants.
    Rolley N; Butcher S; Milner J
    Oncogene; 1995 Aug; 11(4):763-70. PubMed ID: 7651740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of p51/p63 missense mutations on transcriptional activities of p53 downstream gene promoters.
    Kato S; Shimada A; Osada M; Ikawa S; Obinata M; Nakagawara A; Kanamaru R; Ishioka C
    Cancer Res; 1999 Dec; 59(23):5908-11. PubMed ID: 10606233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel human p53 mutations that are toxic to yeast can enhance transactivation of specific promoters and reactivate tumor p53 mutants.
    Inga A; Resnick MA
    Oncogene; 2001 Jun; 20(26):3409-19. PubMed ID: 11423991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of p53 DNA binding activity by point mutation.
    Marston NJ; Ludwig RL; Vousden KH
    Oncogene; 1998 Jun; 16(24):3123-31. PubMed ID: 9671391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dissociation of DNA binding and in vitro transcriptional activities dependent on the C terminus of P53 proteins.
    Kaku S; Albor A; Kulesz-Martin M
    Biochem Biophys Res Commun; 2001 Jan; 280(1):204-11. PubMed ID: 11162500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Xenopus laevis p53 protein: sequence-specific DNA binding, transcriptional regulation and oligomerization are evolutionarily conserved.
    Wang Y; Farmer G; Soussi T; Prives C
    Oncogene; 1995 Feb; 10(4):779-84. PubMed ID: 7862457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction of human polyomavirus BK with the tumor-suppressor protein p53.
    Shivakumar CV; Das GC
    Oncogene; 1996 Jul; 13(2):323-32. PubMed ID: 8710371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of transcription reporters with novel p53 binding sites to target tumour cells expressing endogenous or virally transduced p53 mutants with altered sequence-specificity.
    Gagnebin J; Kovar H; Kajava AV; Estreicher A; Jug G; Monnier P; Iggo R
    Oncogene; 1998 Feb; 16(5):685-90. PubMed ID: 9482117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A conserved intronic response element mediates direct p53-dependent transcriptional activation of both the human and murine bax genes.
    Thornborrow EC; Patel S; Mastropietro AE; Schwartzfarb EM; Manfredi JJ
    Oncogene; 2002 Feb; 21(7):990-9. PubMed ID: 11850816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distance constraints and stereospecific alignment requirements characteristic of p53 DNA-binding consensus sequence homologies.
    Cook JL; Ré RN; Giardina JF; Fontenot FE; Cheng DY; Alam J
    Oncogene; 1995 Aug; 11(4):723-33. PubMed ID: 7651736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
    Perego P; Giarola M; Righetti SC; Supino R; Caserini C; Delia D; Pierotti MA; Miyashita T; Reed JC; Zunino F
    Cancer Res; 1996 Feb; 56(3):556-62. PubMed ID: 8564971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Restoration of the transcription activation function to mutant p53 in human cancer cells.
    Abarzúa P; LoSardo JE; Gubler ML; Spathis R; Lu YA; Felix A; Neri A
    Oncogene; 1996 Dec; 13(11):2477-82. PubMed ID: 8957091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.